Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
02.03.2016
BONESUPPORT™ ANNOUNCES AVAILABILITY IN EUROPE OF CERAMENT™|G IN 5 mL VOLUME TO ADDRESS GROWING MARKET DEMAND

CERAMENT™|G 5 mL to be utilized for infection management and prophylaxis in diabetic foot procedures and small extremities


Lund, Sweden, (PRNEWSWIRE) March 1, 2016 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced an extension to the CERAMENT™|G product portfolio, adding a 5 mL volume to further develop the management of osteomyelitis (OM) and infection prophylaxis in diabetic foot and small extremities. CERAMENT™|G, which releases Gentamicin, received CE-mark in 2013, and is the first injectable antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of bone infection. CERAMENT™|G is now available in 5 mL and 10 mL in CE-mark countries.

Dato
02.03.2016
Veloxis appoints Alastair McEwan as new Chief Operating Officer
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Alastair McEwan has been appointed as Chief Operating Officer.
Dato
02.03.2016
Cydan Development Celebrates Rare Disease Day with Gift to Support the NORD Natural History Project
Cambridge, Mass., February 29, 2016 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that impact the lives of people living with rare genetic diseases, today marked its support of Rare Disease Day with a gift to the National Organization of Rare Disorders (NORD) to support its Natural History Study Project being developed in collaboration with the U.S. Food and Drug Administration. 
Dato
05.02.2016
Phase 2a Psoriasis Study Initiated with Ziarco’s Lead Compound ZPL-389
Discovery Park, Sandwich, UK, - Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs against inflammatory skin disorders, today announced that dosing has started in a Phase 2a proof of concept study in moderate to severe psoriasis with ZPL-389.  The Ziarco study commenced on schedule with results expected in H1 2017.
Dato
05.02.2016
BONESUPPORT™ REPORTS EXPANSION OF COMPANY’S CERAMENT™ DRUG ELUTING PROCEDURE REGISTRY
CERAMENTTM|G registry now includes 230 cases conducted in 18 hospitals across 9 countries - Registry now updated to include CERAMENTTM V procedures
Lund, Sweden, (PRNEWSWIRE) February 2, 2016 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today provided an update on the Company’s CERAMENT™ procedure registry, established by BONESUPPORT™ in February 2014 as part of the proactive postmarket surveillance process for the Company’s novel antibiotic eluting injectable bone substitutes. The CERAMENTTM|G registry now includes 230 cases conducted in 18 hospitals across 9 countries. In addition, the registry has recently been updated to include CERAMENTTM V procedures.


Dato
22.01.2016
BONESUPPORT™ ANNOUNCES APPOINTMENT OF LIFE SCIENCES INDUSTRY VETERAN, RICHARD DAVIES, AS NEW CHIEF EXECUTIVE OFFICER

Mr. Davies Brings over 25 Years of Life Sciences Industry Experience to BONESUPPORT™ Current Chief Executive Officer, Lloyd Diamond, to Transition to Role of Chief Business Officer 

Lund, Sweden, (PRNEWSWIRE) January 22, 2016 – BONESUPPORT™, an emerging leader in both injectable bone substitutes and innovative drug eluting bone scaffold technology for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that the Company has appointed Richard Davies as BONESUPPORT™’s new Chief Executive Officer, effective immediately. Mr. Davies is a senior commercial leader in the life sciences industry with 25 years of global experience in all aspects of sales / marketing and country / regional leadership, a track record of devising and executing growth strategies and delivering successful results in complex situations.

Dato
22.01.2016
Spero Therapeutics Hires Former Biomedical Advanced Research and Development Authority (BARDA) Anti-Infectives Program Chief

Melissa Stundick Joins Leadership Team as Head of Strategic Alliances

CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire-USNewswire/ -- Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced the appointment of Melissa Stundick, Ph.D., to the newly created leadership position of Head of Strategic Alliances.

Dato
12.01.2016
ICONIC THERAPEUTICS CLOSES SERIES C FINANCING WITH NEW AND EXISTING INVESTORS
South San Francisco, CA – January 11, 2016 – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, today announced the closing of a Series C financing bringing $40 million into the company. Proceeds from the financing will be used to advance development of lead molecule ICON-1 in retinal diseases as well as begin clinical trials in ocular melanoma, Iconic’s first oncology indication.  The round included new investors HBM Healthcare Investments, Cormorant Asset Management, and Osage University Partners. All of Iconic’s existing investors, including MPM Capital, H.I.G. Capital and Lundbeckfund Ventures,  participated in the capital raise.
Dato
12.01.2016
BONESUPPORT™ ANNOUNCES 20,000 PATIENTS NOW TREATED WITH CERAMENT
Lund, Sweden, (PRNEWSWIRE) January 11, 2016 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today the Company has reached a significant milestone with more than 20,000 patients treated worldwide with CERAMENT™, a novel injectable and moldable bone substitute with unique drug eluting capabilities.  Adoption of the CERAMENT™ product portfolio continues to grow and gain momentum globally.
Dato
08.01.2016
Enterome announces collaboration with Johnson & Johnson Innovation focused on the discovery of novel targets and therapeutics for Crohn’s disease
Paris, France and Boston, MA, USA – January 7, 2016
Enterome Bioscience SA (“Enterome”), a pioneer in the development of therapeutic solutions based on the gut microbiome, announces that it has entered into a collaborative research agreement with Janssen Biotech, Inc. (Janssen Biotech), one of the Janssen Pharmaceutical Companies of
Johnson & Johnson, and the French National Institute for Agriculture Research (INRA).


Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste